Company intelligence / Profile preview

OssiFi Therapeutics

Kansas City / Overland Park, Kansas, United Statesossifi.com ↗

Ownership: Private
Development stage: Phase 3

Overview

OssiFi develops first-in-class bone-building small molecule inhibitors targeting sclerostin to provide safer and more effective therapies for bone-related conditions. The company aims to outperform current antiresorptive treatments by directly increasing bone density. It has filed multiple patents in the area of rare diseases and skeletal disorders but no published clinical trial results yet.

Therapeutic areas: OtherEndocrinologyRare DiseasesNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

OssiFi sclerostin inhibitor

Preclinical

Partnerships

Binational Industrial Research and Development Foundation (grant funding partner)

Beyond the preview

Go deeper on OssiFi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OssiFi Therapeutics.

Explore the full profile